SAB Biotherapeutics Stock Forecast
NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SABS analyst consensus
Consensus (11 analysts)
none
Avg. price target
$11.64+302.77%
- Strong buy 1
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering SAB Biotherapeutics (2026-10-08), 11 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $11.64, with a high estimate of $16.00 and a low estimate of $6.00. The average target implies upside of 302.8% from the current price of $2.89.
The spread between the highest and lowest targets is 166.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SABS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 9% |
| Buy | 10 | 91% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $6.00 | +107.61% |
| Average target | $11.64 | +302.77% |
| High target | $16.00 | +453.63% |